Basel Medical Group Ltd (NASDAQ:BMGL) Sees Significant Growth in Short Interest

Basel Medical Group Ltd (NASDAQ:BMGL) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 32,559 shares, a growth of 157.1% from the June 30th total of 12,662 shares. Based on an average daily volume of 70,687 shares, the days-to-cover ratio is currently 0.5 days. Approximately 2.1% of the company’s shares are short sold.

Institutional Trading of Basel Medical Group

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new position in shares of Basel Medical Group in the 3rd quarter worth $169,000. Virtu Financial LLC grew its position in Basel Medical Group by 108.8% during the third quarter. Virtu Financial LLC now owns 33,786 shares of the company’s stock valued at $61,000 after acquiring an additional 17,608 shares during the period. Finally, Marex Group plc acquired a new stake in Basel Medical Group during the second quarter worth about $25,000.

Basel Medical Group Trading Down 6.9%

Shares of BMGL stock traded down $0.44 during trading hours on Wednesday, hitting $5.93. 6,168 shares of the company were exchanged, compared to its average volume of 28,640. The firm has a fifty day moving average of $6.83 and a 200 day moving average of $7.49. The company has a current ratio of 1.88, a quick ratio of 1.83 and a debt-to-equity ratio of 0.93. Basel Medical Group has a 1 year low of $4.60 and a 1 year high of $27.36.

Basel Medical Group (NASDAQ:BMGL) last released its earnings results on Friday, June 26th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $3.21 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Basel Medical Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Basel Medical Group has an average rating of “Sell”.

Basel Medical Group Company Profile

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.